DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Kornblum NS, Manola J, Klein P. et al.
PrECOG 0102: A randomized, double-blind phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone-receptor positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy. San Antonio Breast Cancer Symposium 2016; Abstract S1-02.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.